drugset / Trial / NCT06884345
METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
To further evaluate and observe the efficacy and safety of solantinib combined with METR-NK neoadjuvant therapy for advanced epithelial ovarian cancer in patients with advanced epithelial ovarian cancer by using solantinib combined with METR-NK neoadjuvant therapy
Timeline
- Start
- 2025-03-13
- Primary completion
- 2026-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | METR-NK cells | Cell therapy | 4e+07 cells/kg | Other |
| Subject | Solvatinib | Unknown | 250 mg | Oral |